Clumps of alpha-synuclein move through dopamine-producing cells, mouse study finds
Clumps of alpha-synuclein move through dopamine-producing cells, mouse study finds
By Laura Sanders
Web edition: November 16, 2012
A Lewy body, made up of the alpha-synuclein protein (brown) sits inside a neuron in the brain of a patient with Parkinson?s disease.
Credit: Kevin Luk, University of Pennsylvania Perelman School of Medicine
The insidious spread of an abnormal protein may be behind Parkinson?s disease, a study in mice suggests. A harmful version of the protein crawls through the brains of healthy mice, killing brain cells and damaging the animals? balance and coordination, researchers report in the Nov. 16 Science.
If a similar process happens in humans, the results could eventually point to ways to stop Parkinson?s destruction in the brain. ?I really think that this model will increase our ability to come up with Parkinson?s disease therapies,? says study coauthor Virginia Lee of the University of Pennsylvania Perelman School of Medicine in Philadelphia.
The new study targets a hallmark of Parkinson?s disease ? clumps of a protein called alpha-synuclein. The clumps, called Lewy bodies, pile up inside nerve cells in the brain and cause trouble, particularly in cells that make dopamine, a chemical messenger that helps control movement. Death of these dopamine-producing cells leads to the characteristic tremors and muscle rigidity seen in people with Parkinson?s.
Lee and her team injected alpha-synuclein into the brains of healthy mice. After 30 days, the protein had spread to connected brain regions, suggesting that rouge alpha-synuclein moves from cell to cell, the scientists found. Months later, the spreading was even more extensive.
Alpha-synuclein appeared to colonize several areas of the otherwise healthy brain, but the protein was particularly prominent in nerve cells that make dopamine. After six months, Lewy bodies were found inside these cells. As a result, fewer cells survived, and the ones that did churned out less dopamine.
?The real thing here, the novelty, is that the aggregate form can spread from one brain region to another and one cell to another, and cause cell death and disease,? says neuroscientist Patrik Brundin of Van Andel Research Institute in Grand Rapids, Mich.
Overall these animals didn?t show big movement problems, but researchers did find subtle deficits six months after the alpha-synuclein injection. The mice were worse at balancing on a turning rod and couldn?t cling to a wire cage for as long as mice that had been injected with saline.
Scientists don?t know whether such cell-to-cell transmission happens in people, because it?s impossible to do similar studies on humans. But some clues come from the brain of a woman with Parkinson?s who received stem cell transplants in an effort to replenish her missing neurons. Fourteen years after the procedure, Lewy bodies were found in these previously healthy transplanted cells, raising the possibility that alpha-synuclein had spread there from the rest of the brain.
Neurologist and neuroscientist Ted Dawson of Johns Hopkins University School of Medicine cautions that it?s still not clear that the alpha-synuclein spreading has to happen for the protein to cause damage. ?I think transmission occurs,? he says. The real question, he adds, is whether that transmission is important to the disease. ?I don?t think anyone?s answered that in a convincing way.?
If scientists could understand how alpha-synuclein travels from cell to cell in the brain, they could potentially stop the spread, and potentially with it, the disease. Antibodies that slurp up alpha-synuclein as it leaves a cell might prove beneficial, says Dawson.
ufc 143 weigh ins micron ceo glenn miller who do you think you are superpac steve appleton bishop eddie long
Mary Barrow Nichols, senior vice president and general counsel for Texas Mutual Insurance Company, was awarded the 2012 Magna Stella Award for Major Litigation from the Texas General Counsel Forum during an awards dinner for the Forum?s 14th Annual Conference of General Counsel. The Magna Stella Awards program recognizes in-house excellence in Texas corporations, organizations and government agencies. The finalists were nominated by peers and selected by a panel of independent judges. Several hundred corporate counsel, as well as six Texas Supreme Court Justices, attended the dinner where the Magna Stella winners were announced.
They tried not to draw from the corporation because they didn?t want to pay the tax bill. The problem is that when they pass away, the children will want to liquidate the company and will face a big tax bill. Again, insurance can be used to help increase an estate and minimize taxes. We discussed the high passive tax rates on investments in a company. In this case, the company can over time use much of this $1-million to both fund an insurance policy and also possibly shift funds to grow tax free within the insurance policy. The reason is that with certain policies there is an insurance component and an investment component.
She has 70-year-old parents ? at least one of whom is reasonably healthy. The same insurance policy as outlined in example No. 1 can be used but instead of being funded by the parents, it is funded by the 40-year-old couple.
He also has life insurance that he and his wife took out 30 years ago. The doctor?s corporation has $600,000 of investments today. If that doctor gets his life insurance policies properly valued by an actuary, let?s say they are valued at $400,000. In many cases, the doctor can transfer the life insurance policies to his corporation and get a few significant benefits.
If both pass away at age 90, the after tax yield would be over 7% compounded. If one survived until 94 it would still be equivalent to making almost 9% pre-tax somewhere else. That is a return that not many people have seen consistently for over a decade.
The current plan is that their will says to leave 90% of the estate to three named charities. A better alternative for the couple and the charity would be to look at funding an insurance policy with the ?owner? of the policy and the beneficiary of the policy being one of the charities.